Loading clinical trials...
Loading clinical trials...
A Phase 3b, Randomized, Open-Label, Multi-Center Study to Evaluate the Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life.
Conditions
Interventions
MenACWY-CRM
MenACWY-CRM
+1 more
Locations
40
United States
Birmingham, Alabama, United States
Fayetteville, Arkansas, United States
Jonesboro, Arkansas, United States
Little Rock, Arkansas, United States
Fountain Valley, California, United States
Huntington Beach, California, United States
Start Date
October 1, 2010
Primary Completion Date
April 1, 2012
Completion Date
May 1, 2012
Last Updated
October 9, 2018
NCT06131554
NCT01725217
NCT02842866
NCT03205358
NCT03694405
NCT04358731
Lead Sponsor
Novartis Vaccines
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions